Fast Five Quiz: Long-Acting Antiretroviral Therapy for HIV Infection

Michael Stuart Bronze, MD

February 23, 2024

Over the past 20 years, complex and cumbersome HIV treatment regimens have been simplified into a multidrug, once-daily pill for many people with HIV. Recent advances in long-acting antiretroviral therapy (LA-ART) offer further treatment consolidation, reducing dosing frequency per year in some cases.

One such LA-ART, cabotegravir and rilpivirine, was approved by the US Food and Drug Administration in January 2021 and recommended by the UK National Institute for Health and Care Excellence (NICE) as a treatment option for certain HIV patient groups, based on data from the ATLAS and FLAIR trials.

Are you up to date on LA-ARTs for HIV infections? Test your knowledge with this quick quiz.

1 2 3 4 5 6

Next Section

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: Michael Stuart Bronze. Fast Five Quiz: Long-Acting Antiretroviral Therapy for HIV Infection - Medscape - Feb 23, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Fast Five Quiz: Long-Acting Antiretroviral Therapy for HIV Infection

Tables

Authors and Disclosures

Authors and Disclosures

Author(s)

Michael Stuart Bronze, MD

Comments

Email This

Feedback